Due to the amplification of acquired CCNE1 in breast and pancreatic cancers, the cells have acquired resistance to CDK4/6 inhibitors in vitro, damaging the sensitivity of cells to CDK4/6 inhibitors but still rendering them sensitive to CDK2 inhibitors [53, 55]. This evidence concerns the gene CCNE1 and familial pancreatic carcinoma.